✦ LIBER ✦

A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors

✍ Scribed by Darren R. Feldman, Lawrence H. Einhorn, David I. Quinn, Yohann Loriot, Johnathan K. Joffe, David J. Vaughn, Aude Fléchon, Julio Hajdenberg, Abdel-Baset Halim, Hamim Zahir, Robert J. Motzer…show all 11hide

Book ID: 120966765
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 240 KB
Volume: 31
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-013-9934-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tivantinib (ARQ 197), a selective inhibi

Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor–associated tumors : Results of a multicenter phase 2 trial

✍ Andrew J. Wagner; John M. Goldberg; Steven G. DuBois; Edwin Choy; Lee Rosen; Alb 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 307 KB

Phase II trial of edatrexate in relapsed

Phase II trial of edatrexate in relapsed or refractory germ cell tumors: A Southwest Oncology Group study (SWOG 9124)

✍ Frederick J. Meyers; Danika Lew; Primo N. Lara; Steve Williamson; Ernest Marshal 📂 Article 📅 1998 🏛 Springer US 🌐 English ⚖ 48 KB

A phase II trial of a selective c-Met in

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer

✍ Kang, Yoon-Koo; Muro, Kei; Ryu, Min-Hee; Yasui, Hirofumi; Nishina, Tomohiro; Ryo 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 234 KB

Temsirolimus and rituximab in patients w

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study

✍ Stephen M Ansell; Hui Tang; Paul J Kurtin; Patricia A Koenig; David J Inwards; K 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 162 KB

Irinotecan in patients with relapsed or

Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group

✍ Kollmannsberger, C; Rick, O; Klaproth, H; Kubin, T; Sayer, H G; Hentrich, M; Wel 📂 Article 📅 2002 🏛 Nature Publishing Group 🌐 English ⚖ 76 KB

Rituximab monotherapy with eight weekly

Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: A multicenter phase II study

✍ Kensei Tobinai; Tadahiko Igarashi; Kuniaki Itoh; Mitsutoshi Kurosawa; Hirokazu N 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 248 KB